Atlas Trials

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Clinical trial NCT05311319 · UNKNOWN

Trial details

NCT number
NCT05311319
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocarcinoma
Start date
2022-01-11
Primary completion
2022-12-01
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.